SCHEMBL30008747

SCHEMBL30008747

c1cc(-c2ccc(OCCN3CCOCC3)cc2)c2cc[nH]c2n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NEK1 Q96PY6 2/20 0.64
JAK1 P23458 1/20 0.61
MAPK8 P45983 3/20 0.56
CAMKK2 Q96RR4 3/20 0.56
CHUK O15111 2/20 0.53
INSR P06213 2/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
TBK1 Q9UHD2 1/20 0.50
PRKCQ Q04759 1/20 0.50
PRKCD Q05655 1/20 0.50
PRKAB1 Q9Y478 4/20 0.48
PRKAB2 O43741 3/20 0.48
PRKAG1 P54619 3/20 0.48
PRKAA2 P54646 3/20 0.48
PRKAA1 Q13131 3/20 0.48
PRKAG3 Q9UGI9 3/20 0.48
PRKAG2 Q9UGJ0 3/20 0.48
KDR P35968 2/20 0.48
LCK P06239 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4792087 0.81 NEK1 (0.62) NEK1MAPK8CAMKK2CHUKINSR
SCHEMBL31289890 0.81 NPC1 (0.57) JAK1NPC1RAB9APRKCQPRKCD
SCHEMBL4830288 0.78 NEK1 (0.58) NEK1MAPK8CHUKTBK1PRKCQ
SCHEMBL858754 0.77 IKBKB (0.57) NEK1MAPK8CHUKPRKCQPRKAA1
SCHEMBL30009109 0.77 IKBKB (0.57) NEK1MAPK8CHUKPRKCQPRKAA1
SCHEMBL30356217 0.76 JAK1 (1.00) JAK1
SCHEMBL20919169 0.76 JAK1 (1.00) JAK1
SCHEMBL5395486 0.76 CCNK (0.60) NEK1MAPK8CHUKPRKCQPRKAA1
SCHEMBL1717834 0.73 NEK1 (0.53) NEK1MAPK8CAMKK2CHUKTBK1
SCHEMBL4873430 0.73 IKBKB (0.60) NEK1JAK1MAPK8CHUKPRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US claimed
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor MAP3K20, MAP3K15, MAP3K1 NEK1 178/4885JAK1 83/4885MAPK8 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.